TOTAL SYNTHESIS OF (-)-EBELACTONE-A AND (-)-EBELACTONE-B-1

被引:62
作者
PATERSON, I
HULME, AN
机构
[1] University Chemical Laboratory, Cambridge, CB2 1EW, Lensfleld Road
[2] Department of Chemistry, The University of Edinburgh, King’s Buildings, Edinburgh, EH9 3JJ, West Mains Road
关键词
D O I
10.1021/jo00116a010
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The beta-lactone enzyme inhibitors (-)-ebelactone A (1) and (-)-ebelactone B (2) have been prepared in 12 steps from diethyl ketone (4 and 3% overall yield, respectively). The synthetic strategy adopted for the ebelactones demonstrates the use of reagent- and substrate-derived stereocontrol and requires the minimal use of protecting groups. The stereocenters at C-2, C-3, C-8, C-10, and C-11 were constructed using boron aldol methodology. An asymmetric syn, aldol addition of diethyl ketone to 2-ethyl/acrolein gave adduct 8 in 86% ee, followed by a diastereoselective syn aldol reaction to give 11. Subsequently, an Ireland-Claisen rearrangement was used to relay 1,2-syn into 1,5-syn relative stereochemistry, as in 12 --> 14. In the anti aldol construction of the C-2-C-3 bond, the use of either a propionate or butyrate thioester enolate allowed for a divergent approach from aldehyde 17 to both (-)-ebelactone A and B. Several novel analogues of ebelactone A and B were also prepared with inverted stereochemistry at C-2, C-3, or C-12.
引用
收藏
页码:3288 / 3300
页数:13
相关论文
共 99 条
  • [1] Umezawa H., Takaaki A., Uotani K., Hamada M., Takeuchi T., Takahashi S., J. Antibiot., 33, (1980)
  • [2] Uotani K., Naganawa H., Kondo S., Aoyagi T., Umezawa H., J. Antibiot., 35, (1982)
  • [3] Uotani K.
  • [4] Macrolide Antibiotics: Chemistry, Biology and Practice’, (1984)
  • [5] Uotani K., Naganawa H., Aoyagi T., Umezawa H., J. Antibiot., 35, (1982)
  • [6] Kondo S., Uotani K., Miyamoto M., Hazato T., Naganawa N., Aoyagi T., Umezawa H., J. Antibiot., 31, (1978)
  • [7] Kitahara M., Asano M., Naganawa H., Maeda K., Hamada M., Aoyagi T., Umezawa H., Iitaka Y., Nakamura H., J. Antibiot., 40, (1987)
  • [8] Wiebel E.K., Hadvary P., Hochuli E., Kupfer E., Lengsfeld H., J. Antibiot., 40, (1987)
  • [9] Greenspan M.D., Yudkovitz J.B., Lo C.-Y.L., Chen J.S., Alberts A.W., Hunt V.M., Chang M.N., Yang S.S., Thompson K.L., Chiang Y.-C.P., Chabala J.C., Monaghan R.L., Schwartz R.E., Proc. Natl. Acad. Sci. U. S. A., 84, (1987)
  • [10] Wells J.S., Trejo W.H., Principe P.A., Sykes R.B., J. Antibiot., 37, (1984)